

# Anti-viral Effect of *Bifidobacterium adolescentis* against Noroviruses

Dan Li, Adrien Breiman, Jacques Le Pendu, Mieke Uyttendaele

► **To cite this version:**

Dan Li, Adrien Breiman, Jacques Le Pendu, Mieke Uyttendaele. Anti-viral Effect of *Bifidobacterium adolescentis* against Noroviruses. *Frontiers in Microbiology*, *Frontiers Media*, 2016, 7, pp.864. 10.3389/fmicb.2016.00864 . inserm-01406298

**HAL Id: inserm-01406298**

**<https://www.hal.inserm.fr/inserm-01406298>**

Submitted on 1 Dec 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# Anti-viral Effect of *Bifidobacterium adolescentis* against Noroviruses

Dan Li<sup>1\*</sup>, Adrien Breiman<sup>2,3,4,5</sup>, Jacques le Pendu<sup>2,3,4†</sup> and Mieke Uyttendaele<sup>1†</sup>

<sup>1</sup> Laboratory of Food Microbiology and Food Preservation, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium, <sup>2</sup> UMR 892, Institut National de la Santé et de la Recherche Médicale, Nantes, France, <sup>3</sup> UMR 6299, Centre National de la Recherche Scientifique, Nantes, France, <sup>4</sup> Faculty of Medicine, University of Nantes, Nantes, France, <sup>5</sup> Nantes University Hospital, Nantes, France

This study aims to investigate the effect of *Bifidobacterium adolescentis* against noroviruses (NoVs). Murine norovirus-1 (MNV-1) used as a surrogate was detected by plaque assay and RT-qPCR. Human NoV virus like particles (VLPs) were detected by cell-binding assay. It was shown that the presence of *B. adolescentis* could inhibit the multiplication of MNV-1 on RAW 264.7 cells within 48 h of co-incubation period at 37°C. This inhibition did not occur at the viral binding stage, as no difference was observed in MNV-1 genomic copies collected from washed RAW 264.7 cells without and with *B. adolescentis* after co-incubation for 1 h at room temperature. Meanwhile, the presence of *B. adolescentis* decreased the binding of human NoV GI.1 VLPs to both Caco-2 cells and HT-29 cells, while no reduction was induced for the binding of human NoV GII.4 VLPs to Caco-2 cells.

**Keywords:** Norovirus, *Bifidobacterium adolescentis*, probiotics, mechanisms

## INTRODUCTION

Probiotics are defined as “living micro-organisms, which upon ingestion in certain numbers, exert health benefits beyond inherent basic nutrition.” Most probiotic microorganisms belong to lactic acid bacteria (LAB), such as *Lactobacillus* sp., *Bifidobacterium* sp., and *Enterococcus* sp (Ljungh and Wadström, 2006). Probiotics may benefit the human and animal host directly, by preventing the infection and combating the causative agent of the intestinal disorder, or indirectly, by balancing the disrupted equilibrium of the enteric flora and augmenting the host’s immune responses (Maragkoudakis et al., 2010; Sanders et al., 2013). Clinical evidence has reported that feeding of probiotics can prevent effectively for diarrhea and shedding of rotavirus (Saavedra et al., 1994; Van Niel et al., 2002; Sazawal et al., 2006; Grandy et al., 2010). Accordingly, with the use of animal models, multiple probiotic strains have shown anti-rotavirus effect (Muñoz et al., 2011; Kandasamy et al., 2014; Mao et al., 2016). In addition, *in vitro* studies have demonstrated that probiotics may have antiviral activity against rotavirus (Maragkoudakis et al., 2010; Muñoz et al., 2011), coxsackievirus (Kim et al., 2014), hepatitis C virus (El-Adawi et al., 2015), as well as noroviruses (NoVs; Aboubakr et al., 2014; Rubio-del-Campo et al., 2014).

Noroviruses, one genera of the *Caliciviridae* family, were reported as the cause of between 73% to greater than 95% of global epidemic nonbacterial gastroenteritis outbreaks and approximately half of all gastroenteritis outbreaks (Atmar and Estes, 2006). Although NoV infections are generally mild, it may require hospital care and can be associated with mortality in elderly, chronically ill or immune-compromised patients. Taking into consideration their widespreadness, NoVs are causing heavy disease burdens associated with large economic losses (Van Beek et al., 2013). Despite recent

## OPEN ACCESS

### Edited by:

David Berry,  
University of Vienna, Austria

### Reviewed by:

Douglas Morrison,  
University of Glasgow, UK  
Lorena Ruiz,  
Universidad Complutense de Madrid,  
Spain

### \*Correspondence:

Dan Li  
dan.li@ugent.be

<sup>†</sup> These authors are co-senior authors.

### Specialty section:

This article was submitted to  
Microbial Symbioses,  
a section of the journal  
Frontiers in Microbiology

**Received:** 23 January 2016

**Accepted:** 23 May 2016

**Published:** 08 June 2016

### Citation:

Li D, Breiman A, le Pendu J and  
Uyttendaele M (2016) Anti-viral Effect  
of *Bifidobacterium adolescentis*  
against Noroviruses.  
*Front. Microbiol.* 7:864.  
doi: 10.3389/fmicb.2016.00864

progress, several key challenges remain in assessing the efficacy of vaccines and antiviral drugs for human NoV infection, such as the lack of a robust cell culture system or animal model limits direct study of these viruses, and the extreme genetic heterogeneity among strains (Karst et al., 2014). Therefore, it is of high interest to investigate further if probiotics can be employed for NoV control and treatment.

In this study, due to the non-cultivability of human NoVs, murine norovirus-1 (MNV-1, a very commonly used human NoV surrogate, Kniel, 2014), and human NoV virus like particles (VLPs) were used to study the effect of *Bifidobacterium adolescentis* against NoVs.

## MATERIALS AND METHODS

### Bacteria

*Bifidobacterium adolescentis* (LMG10502, biological origin: adult intestines) was obtained from Belgian Coordinated Collection of Microorganisms (BCCM/LMG). *B. adolescentis* was cultured in tryptone soya broth (TSB, Oxoid, Thermo) at 37°C. The anaerobic atmosphere was generated with the use of ANAEROGEN™ COMPACT (Oxoid, Thermo).

Before each experiment, *B. adolescentis* were cultured for 48 h, normalized to an OD<sub>570</sub> of 0.4, and washed twice with phosphate buffered saline (PBS, pH 7.4).

### Cell Lines, Virus, and Virus-Like Particles (VLPs)

Cells of the murine macrophage cell line RAW 264.7 (ATCC TIB-71; kindly provided by Prof. H. W. Virgin, Washington University School of Medicine, St. Louis, MO, USA) were maintained in complete DMEM medium and grown at 37°C under a 5% CO<sub>2</sub> atmosphere. Complete DMEM consisted of Dulbecco's modified Eagle's medium (DMEM; Lonza, Walkersville, MD, USA) containing 10% low-endotoxin fetal bovine serum (HyClone, Logan, UT, USA), 100 U/ml penicillin, 100 µg/ml streptomycin (Lonza), 10 mM HEPES (Lonza), and 2 mM L-glutamine (Lonza).

RAW 264.7 cells were infected with MNV-1.CW1 and passaged seven times at a multiplicity of infection (MOI) of 0.05 (MNV-1:cells) for 2 days. After two freeze-thaw cycles, low speed centrifugation was used to remove cellular debris from the virus suspension, as described by Wobus et al. (2004). The lysate containing suspended MNV-1 was stored in aliquots at -75°C.

Cell line Caco-2 (ECACC 86010202) was cultured in Eagle's minimum essential medium with Earle's salts (EMEM; Lonza) supplemented with 10% low-endotoxin fetal bovine serum (HyClone), 100 U/ml penicillin, 100 µg/ml streptomycin (Lonza), and 2 mM L-glutamine (Lonza) and grown at 37°C under a 5% CO<sub>2</sub> atmosphere. HT-29 (ATCC HTB-38) cells were cultured in Dulbecco's modified Eagle's medium (DMEM; GIBCO®, Life Technologies.) supplemented with 10% low-endotoxin fetal bovine serum (GIBCO®, Life Technologies), 100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO®, Life Technologies), and 2 mM L-glutamine (GIBCO®, Life Technologies) and grown at 37°C under a 5% CO<sub>2</sub> atmosphere.

Virus-like particles of human NoV GI.1 (Norwalk virus) and GII.4 (Dijon 1996) were generated using a previously described method (Jiang et al., 1992). Recombinant baculoviruses containing the VP1 protein from NoV GI.1 and GII.4 were generated, and VLPs were produced by infection of Hi5 insect cells. VLPs were released from the infected Hi5 cells by three rounds of freeze-thawing and then clarified by removal of cellular debris (6,000 × g for 30 min) and baculovirus (14,000 × g for 30 min). The VLPs were partially purified through a 30% (wt/vol) sucrose cushion in TNC buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM CaCl<sub>2</sub>) containing the protease inhibitor leupeptin at 150,000 × g for 2 h. The pelleted VLPs were resuspended in TNC and further purified by isopycnic centrifugation in cesium chloride (150,000 × g; 18 h). The resultant VLP bands were collected by puncture, and the solution containing VLPs was dialyzed against PBS prior to quantification by bicinchoninic acid (BCA) protein assay (Thermo Scientific) and stored at -80°C.

### Cytotoxicity Test-Neutral Red Assay

The cytotoxicity of bacteria on RAW 264.7 cells was measured by a neutral red assay based on the description by Fotakis and Timbrell (2006) with a few modifications. The RAW 264.7 cells were seeded into 96-well plates at a density of 10<sup>5</sup> viable cells per well. On the following day, the RAW 264.7 cells were washed with PBS to remove the antibiotics, the *B. adolescentis* re-suspended in DMEM (Lonza) were added onto the cells (50 µl per well) and incubated for 1 h at room temperature. Afterward the inoculum was aspirated and fresh complete DMEM without antibiotics was added (100 µl per well). Plates were incubated at 37°C and 5% CO<sub>2</sub>.

After 2 days incubation, the medium of the cells was changed to neutral red dye (Sigma-Aldrich, St. Louis, MO, USA, 100 µg/ml) dissolved in DMEM (100 µl per well) and incubated for another 2 h at 37°C and 5% CO<sub>2</sub>. Cells were then washed with PBS and the addition of elution medium (EtOH/AcCOOH, 50%/1%, 100 µl per well) followed by gentle shaking for 10 min so that complete dissolution was achieved. The optical density was read at 540 nm (OD<sub>540</sub>).

### Viral Multiplication Inhibition Test on MNV-1 Detected by Plaque Assay

The RAW 264.7 cells were seeded into six-well plates at a density of 2 × 10<sup>6</sup> viable cells per well. On the following day, the *B. adolescentis* re-suspended in DMEM (Lonza) was used to make ten-fold dilutions from MNV-1 lysate. The RAW 264.7 cells were washed with PBS to remove the antibiotics, the mixture of bacteria and MNV-1 was added onto the cells (500 µl per well, two wells per sample). Plates were incubated for 1 h at room temperature and manually rocked every 15 min before aspirating the inoculum and overlaying the cells with 1.5% SeaPlaque agarose (Cambrex, Rockland, ME, USA) in MEM (Lonza) supplemented with 10% low-endotoxin fetal bovine serum, 1% HEPES, 1% penicillin/streptomycin, and 2% glutamine (complete MEM) per well. Plates were incubated at 37°C and 5% CO<sub>2</sub> for 2 days. To visualize plaques, cells were stained with 1.5%

SeaKem agarose in complete MEM containing 1% neutral red (Sigma–Aldrich) per well for 6 h.

Plaque sizes were shown to be associated with the virulence in multiple studies (Takemoto, 1966; Lipton, 1980). In this study, from photos taken from each group with the same format and size, the diameters of plaques were measured and recorded by the use of ImageJ (National Institutes of Health, Bethesda, MD, USA).

## Viral Binding Inhibition Test on MNV-1 Detected by RT-qPCR

The RAW 264.7 cells were seeded into 96-well plates at a density of  $10^5$  viable cells per well. On the following day, the *B. adolescentis* was re-suspended in MNV-1 dilutions with DMEM (50  $\mu$ l per sample, with  $5.8 \pm 0.1$  log MNV-1 genomic copies per sample). The RAW 264.7 cells were washed with PBS to remove the antibiotics, the mixture of bacteria and MNV-1 were added onto the cells (50  $\mu$ l per well) and incubated for 1 h at room temperature. Afterward the inoculum was aspirated and the cells were washed by PBS for three times.

The RNAs of washed cells were extracted by using the RNeasy Mini kit (Qiagen, Hilden, Germany). For each sample the 100  $\mu$ l PBS was firstly mixed with 350  $\mu$ l lysis buffer, and the mixture was pipetted back onto the cells in the 96-well plates in order to lyse the cells. The following procedures were performed according to the RNA Cleanup protocol and the RNA were stored at  $-75^\circ\text{C}$ .

The RT-qPCR of MNV-1 was performed by the use of RNA UltraSense™ One-Step Quantitative RT-PCR System (Life technologies). The primers and probe sequence of MNV-1 were previously shown by Baert et al. (2008). Twenty micro liter of reaction mixture [200 nM each primer, 200 nM probe, 50 nM ROX (Life technologies)] was added to 5  $\mu$ l of RNA. The RT-qPCR assays were performed in an ABI 7300 system (Applied Biosystems). The amplification profile consisted of  $50^\circ\text{C}$  for 15 min,  $95^\circ\text{C}$  for 2 min and 45 cycles of  $95^\circ\text{C}$  for 15 s and  $60^\circ\text{C}$  for 30 s.

An absolute quantification of MNV-1 genomic copies was performed as described by Baert et al. (2008). To obtain representative positive control standards, the plasmid p20.3 containing a full-length cDNA clone of MNV-1.CW1 (Baert et al., 2008) was used for the quantifications. Ten-fold serial dilutions ranging from  $10^6$  to 10 copies of plasmids per reaction were used to prepare the standard curves.

## Viral Binding Inhibition Test on Human NoV VLPs Detected by Fluorescence Measurement

The HT-29 cells were seeded into 96-well plates at a density of  $10^5$  viable cells per well. On the following day, the *B. adolescentis* was re-suspended in NoV GI.1 VLP suspension [5  $\mu$ g/ml, in PBS-0.1% bovine serum albumin (BSA)]. The mixture of bacteria and VLPs was added onto the cells (50  $\mu$ l per well) and incubated for 1 h at room temperature. After washing with PBS for three times, the cells were fixed with 4% paraformaldehyde, and stained by anti-VLP rabbit polyclonal antibodies (Ip130 for GI.1, diluted in PBS-0.1% BSA, 1-h incubation at  $37^\circ\text{C}$ ) followed by

Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L) antibody (Life Technologies, diluted in PBS-0.1% BSA, 1-h incubation at  $37^\circ\text{C}$ ). Three times washing by PBS was always performed after each step. The fluorescence was read by a fluorimeter (Fluoroskan, Thermo Scientific; Ex/Em = 490/525 nm) in arbitrary unit (a.u.).

The binding test of human NoV GI.1 and GII.4 VLPs (anti-VLP rabbit polyclonal antibodies Ip130 for GI.1 and Ip132 for GII.4) on Caco-2 cell were similar with the procedures above except that the Caco-2 cells were incubated for 21 days post confluency to be used as differentiated cells.

The binding of NoV GI.1 VLPs to HT-29 cells was also observed with a fluorescence microscope. The HT-29 cells were seeded into eight-well Nunc® Lab-Tek® Chamber Slide System (Sigma–Aldrich) at a density of  $10^5$  viable cells per well. On the following day, the binding and staining steps were the same as described above. After the last washing step (from the secondary antibody incubation), the upper structure was removed from the bottom glass slide. The stained cells were mounted on slides with Vectashield® (Vector laboratories, Burlingame, CA, USA). The sealed slides were observed under a Zeiss Axiovert 200 fluorescence microscope.

## Data Analysis

Each result was presented as the mean value of three independent replicates with the standard deviation. Statistical analyses were performed by Mann–Whitney *U* test with SPSS 22 for Windows (SPSS, Inc., Chicago, IL, USA). Significant differences were considered when *P* was  $<0.05$ .


## RESULTS

### Effect of *B. adolescentis* on MNV-1 Infectivity

First of all, after 48 h incubation, the cell viability determined by neutral red assay showed no significant reduction after incubation of the RAW 264.7 cells with *B. adolescentis* ( $\text{OD}_{540}$   $1.1 \pm 0.1$ – $1.1 \pm 0.2$ ,  $P > 0.05$ ).

MNV-1 lysate was diluted to a concentration that can form countable plaques on the six-well plates, and was seeded onto the cells with or without *B. adolescentis*. The plaque assay showed that compared with the negative control (MNV-1 on RAW 264.7 cells without bacteria), the MNV-1 plaque forming units (PFU) from cell-culture wells in the presence of *B. adolescentis* were decreased significantly from  $20 \pm 3$ – $7 \pm 2$  PFU/well (Figure 1A,  $P < 0.05$ ).

It was also noticed that the sizes of the plaques from cells incubated with *B. adolescentis* were smaller than the negative control (examples shown in Figure 1C). The average sizes of the plaques measured by ImageJ showed that compared with the negative control (MNV-1 on RAW 264.7 cells without bacteria), the plaque diameters from cell-culture wells in the presence of *B. adolescentis* were decreased significantly from  $9.2 \pm 2.7$ – $3.9 \pm 0.6$  pixel (Figure 1B,  $P < 0.05$ ). These results indicate that the effect of *B. adolescentis* on MNV-1 may occur mainly in the viral replication phase instead of showing direct virucidal effect on the MNV-1 or preventing the viruses from binding to the cells.



**FIGURE 1 | MNV-1 multiplication inhibition by *B. adolescentis* determined by plaque assay. (A)** Plaque forming units (PFU) from cell-culture wells with and without *B. adolescentis*. Each data point is an average of three independent tests, and each error bar represents the data range. \* $P < 0.05$ . **(B)** Plaque diameters from cell-culture wells with and without *B. adolescentis*. Each data point is an average of 15 measurements, and each error bar represents the data range. \* $P < 0.05$ . **(C)** Plaque appearances from cell-culture wells with and without *B. adolescentis*.

Therefore lastly, a viral binding inhibition test was performed and indeed no significant difference of MNV-1 genomic copies collected from RAW 264.7 cells between the two groups with ( $5.77 \pm 0.03$  log-genomic copies/ml) and without *B. adolescentis* ( $5.74 \pm 0.01$  log-genomic copies/ml) was observed ( $P > 0.05$ ).

### Effect of *B. adolescentis* on Human NoV VLPs Cell-Binding Ability

It has been previously reported that both VLPs of human NoV GI.1 and GII.4 could bind to Caco-2 cells (Tamura et al., 2004) and VLPs of human NoV GI.1 could bind to HT-29 cells (Rubio-del-Campo et al., 2014).


The presence of *B. adolescentis* decreased the binding of human NoV GI.1 VLPs to Caco-2 cells, measured by fluorescence intensity, significantly from  $45.2 \pm 5.0$  (negative control without bacteria) to  $33.0 \pm 4.6$  a.u. (incubation with *B. adolescentis*; **Figure 2A**,  $P < 0.05$ ).

The fluorescence intensity of human NoV GI.1 VLPs on HT-29 cells also decreased, although not significantly, from  $92.0 \pm 25.0$  to  $52.0 \pm 5.0$  a.u. by the incubation of *B. adolescentis* (**Figure 2B**,  $P = 0.05$ ). A visual example detected by fluorescence microscopy was shown in **Figure 2C**.

As for human NoV GII.4 VLPs, no significant reduction was observed for the binding of the VLPs to Caco-2 cells with the incubation of *B. adolescentis* ( $19.0 \pm 1.7$  to  $17.7 \pm 0.6$  a.u.,  $P > 0.05$ ).

## DISCUSSION

Currently, the research on the effect of probiotics on NoVs are still preliminary. On one hand, due to the non-cultivability of human NoVs, the *in vitro* studies were conducted with the use of surrogate viruses [e.g., feline calicivirus (FCV), Aboubakr et al., 2014; MNV-1 and Tulane virus (TV), Shearer et al., 2014] and artificially synthesized particles partially mimicking the viral structures (*P*-particles, Rubio-del-Campo et al., 2014), which may introduce gaps from the authentic NoV reactions. On the other hand, there are an insufficient number of in-depth studies on this topic before a general conclusion can be drawn. For instance, it was reported that the fermentation of *Donchimi* and oysters could effectively reduce the infectivity of FCV and MNV-1 (Lee et al., 2012; Seo et al., 2014). The population of LAB increased largely during the fermentation, however, it was neither clear on the role that the LAB played nor the associated mechanisms (Lee et al., 2012; Seo et al., 2014). For another instance, high infectivity reduction (6–7-log reduction) was observed for FCV following co-incubation with *Lactococcus lactis* (both bacterial medium filtrate and cells suspension, Aboubakr et al., 2014). However, the cell-free supernatant of a commercial probiotic mixture of *Lactobacillus acidophilus*, *Lactobacillus rhamnosus*, *Bifidobacterium bifidum*, *Lactobacillus salivarius*, and *Streptococcus thermophilus* indicated no reduction for the infectivity of MNV and TV (Shearer et al., 2014). The reasons causing the inconsistency of the studies can be the differences between both of the studied viruses and bacteria strains, as well as the experimental settings such as time/sequence



**FIGURE 2 | Human NoV GI.1 VLPs binding inhibition by *B. adolescentis*.**

**(A)** Fluorescence measurement in arbitrary unit (a.u.) of human NoV GI.1 VLPs bound to Caco-2 cells. Each data point is an average of three independent tests, and each error bar represents the data range. \* $P < 0.05$ .

**(B)** Fluorescence measurement in arbitrary unit (a.u.) of human NoV GI.1 VLPs bound to HT-29 cells. Each data point is an average of three independent tests, and each error bar represents the data range. **(C)** Fluorescence microscope observation of human NoV GI.1 VLPs bound to HT-29 cells.

of addition, comparative ratio of viruses and bacteria, incubation conditions (time, atmosphere and temperature) and matrices, etc.

In this study, MNV-1 was employed as the surrogate as it was more persistent than FCV in the fermentation of both *Donchimi* and oysters (Lee et al., 2012; Seo et al., 2014). Human NoV VLPs from GI.1 and GII.4 were used as they could mimic the binding capacity of two representative NoV genotypes. *B. adolescentis* is a recognized probiotics (Lee et al., 1993; Kim et al., 2008) and has interested dairy manufacturers in producing “therapeutic fermented milk products” (Arunachalam, 1999; Puniya, 2015). Also it was reported recently to exhibit antiviral activity against Coxsackievirus (Kim et al., 2014). The bacterial cells were washed

with PBS before being added to the viruses and cells in order to avoid any direct virucidal effect of the bacterial metabolites in the culture medium, such as organic acids, diacetyl, and bacteriocins. The bacteria and viruses (MNV-1 and human NoV VLPs) were co-incubated with the cells as this strategy was shown to be more effective than pre-treatment of cells, pre-treatment of viruses (Aboubakr et al., 2014; Rubio-del-Campo et al., 2014), or post-treatment of cells attached to viruses (Rubio-del-Campo et al., 2014).

It was demonstrated in this study that the presence of *B. adolescentis* could inhibit the multiplication of MNV-1 on RAW 264.7 cells. Meanwhile, it was shown that this inhibition effect did not occur on the binding stage of MNV-1 to RAW 264.7 cells. However, in contrast, the presence of *B. adolescentis* did decrease the binding of human NoV GI.1 VLPs to both Caco-2 cells and HT-29 cells. Although based on different models, these results indicate that the effects of *B. adolescentis* on different viruses might vary based on different mechanisms.

It was reported previously that NoV P-particles could bind to a series of probiotics with varied binding ability, which was postulated as one of the antiviral mechanisms of the probiotics (Rubio-del-Campo et al., 2014). However, based on a recent study of our group (Li et al., 2015), the *B. adolescentis* strain used in this study does not express histo-blood group antigen (HBGA) and could not bind to NoV VLPs of either GI.1 or GII.4. This result rules out the possibility of direct competition of *B. adolescentis* and NoV GI.1VLPs from binding to Caco-2 or HT-29 cells. Instead, as we and others have described a few bacterial lectins binding to HBGAs (Gilboa-Garber et al., 2011; Audfray et al., 2012) and Zhong et al. (2004) have reported that the adhesion of *B. adolescentis* 1027 could inhibit the adhesion of *Escherichia coli* to intestinal epithelial cell line Lovo, we assume that certain lectins secreted by *B. adolescentis* could bind to the HBGAs on the intestinal cell lines and compete with the binding of NoV GI.1VLPs.

As the binding of human NoV GI.1 VLPs to both Caco-2 cells and HT-29 cells was decreased in the presence of *B. adolescentis*, it is reasonable to assume that the viral multiplication of human NoV GI.1, if an *in vitro* model could be established, should also be decreased in the presence of *B. adolescentis*. On the other hand, although no reduction of the binding of human NoV GII.4 VLPs to Caco-2 cells was observed in the presence of *B. adolescentis*, the possibility cannot be ruled out that *B. adolescentis* may reduce the viral multiplication of human NoV GII.4 if an *in vitro* model could be established, or help combat NoVs *in vivo*. The differences observed between the two strains are not surprising as it is well known that the chemical

structures of the receptor binding interfaces are different between NoV GI.1 and GII.4 (Tan and Jiang, 2011). However, the exact molecular mechanisms causing the influence of *B. adolescentis* on human NoV VLPs binding to intestinal cell lines still need further investigation.

## CONCLUSION

This study demonstrated the antiviral effect of *B. adolescentis* against NoVs. Due to the lack of models to study the infection of genuine human NoVs, the results were generated from studying surrogates detected by different methods (infection and binding of MNV-1 on murine macrophage cell line RAW 264.7 and binding of human NoV VLPs on human intestinal epithelial cell lines Caco-2 and HT-29). Since the effects of *B. adolescentis* on MNV-1 and human NoV VLPs as well as their mechanisms were indicated to be different, this study shows the importance of establishing multiplication model for human NoVs in the future. In addition, more probiotic strains will be tested before a general conclusion can be drawn on the antiviral effect of probiotics on NoV infection.

## AUTHOR CONTRIBUTIONS

DL performed most of the experiments and composed the manuscript. AB supplied technical support for the experiments, especially for the fluorescence microscope as well as improvement of the manuscript. JP and MU gave strategic guidance for the work and suggestions to improve the manuscript.

## FUNDING

This study was supported by a postdoctoral grant (DL.) and a financial support for staying abroad (DL.) from the Research Foundation-Flanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen) and by a grant from the Region des Pays de la Loire (ARMINA).

## ACKNOWLEDGMENT

The authors also acknowledge the help of imaging core facilities of the University of Nantes (Micropicell).

## REFERENCES

- Aboubakr, H. A., El-Banna, A. A., Youssef, M. M., Al-Sohaimy, S. A., and Goyal, S. M. (2014). Antiviral effects of *Lactococcus lactis* on feline calicivirus, a human norovirus surrogate. *Food Environ. Virol.* 6, 282–289. doi: 10.1007/s12560-014-9164-2
- Arunachalam, K. D. (1999). Role of bifidobacteria in nutrition, medicine and technology. *Nutrition Res.* 19, 1559–1597. doi: 10.1016/j.anaerobe.2015.05.012
- Atmar, R. L., and Estes, M. K. (2006). The epidemiologic and clinical importance of norovirus infection. *Gastroenterol. Clin. North Am.* 35, 275–290. doi: 10.1016/j.gtc.2006.03.001
- Audfray, A., Claudinon, J., Abounit, S., Ruvoën-Clouet, N., Larson, G., Smith, D. F., et al. (2012). Fucose-binding lectin from opportunistic pathogen *Burkholderia ambifaria* binds to both plant and human oligosaccharidic epitopes. *J. Biol. Chem.* 287, 4335–4347. doi: 10.1074/jbc.M111.314831
- Baert, L., Wobus, C. E., Van Coillie, E., Thackray, L. B., Debevere, J., and Uyttendaele, M. (2008). Detection of murine norovirus 1 by using

- plaque assay, transfection assay, and real-time reverse transcription-PCR before and after heat treatment. *Appl. Environ. Microbiol.* 74, 543–546. doi: 10.1128/AEM.01039-07
- El-Adawi, H., Nour, I., Fattouh, F., and El-Deeb, N. (2015). Investigation of the antiviral bioactivity of *Lactobacillus bulgaricus* 761N extracellular extract against hepatitis C virus (HCV). *Int. J. Pharm.* 11, 19–26. doi: 10.3923/ijp.2015.19.26
- Fotakis, G., and Timbrell, J. A. (2006). In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. *Toxicol. Lett.* 160, 171–177.
- Gilboa-Garber, N., Zinger-Yosovich, K. D., Sudakevitz, D., Lerrer, B., Imbert, A., Wimmerova, M., et al. (2011). “The five bacterial lectins (PA-IL, PA-III, RSL, RS-III, and CV-III): interactions with diverse animal cells and glycoproteins,” in *The Molecular Immunology of Complex Carbohydrates-3*, ed. A. M. Wu (New York, NY: Springer), 155–211.
- Grandy, G., Medina, M., Soria, R., Terán, C. G., and Araya, M. (2010). Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. *BMC Infect. Dis.* 10:253. doi: 10.1186/1471-2334-10-253
- Jiang, X., Wang, M., Graham, D. Y., and Estes, M. K. (1992). Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. *J. Virol.* 66, 6527–6532.
- Kandasamy, S., Chattha, K. S., Vlasova, A. N., Rajashekar, G., and Saif, L. J. (2014). Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. *Gut Microbes* 5, 639–651. doi: 10.4161/19490976.2014.969972
- Karst, S. M., Wobus, C. E., Goodfellow, I. G., Green, K. Y., and Virgin, H. W. (2014). Advances in norovirus biology. *Cell Host Microbe* 15, 668–680. doi: 10.1016/j.chom.2014.05.015
- Kim, M. J., Lee, D. K., Park, J. E., Park, I. H., Seo, J. G., and Ha, N. J. (2014). Antiviral activity of *Bifidobacterium adolescentis* SPM1605 against Coxsackievirus B3. *Biotechnol. Biotechnol. Equip.* 28, 681–688. doi: 10.1080/13102818.2014.945237
- Kim, Y., Lee, D., Kim, D., Cho, J., Yang, J., Chung, M., et al. (2008). Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by *Bifidobacterium adolescentis* SPM0212. *Arch. Pharm. Res.* 31, 468–473. doi: 10.1007/s12272-001-1180-y
- Kniel, K. E. (2014). The makings of a good human norovirus surrogate. *Curr. Opin. Virol.* 4, 85–90. doi: 10.1016/j.coviro.2014.01.002
- Lee, J., Ametani, A., Enomoto, A., Sato, Y., Motoshima, H., Ike, F., et al. (1993). Screening for the immunopotentiating activity of food microorganisms and enhancement of the immune response by *Bifidobacterium adolescentis* M101-4. *Biosci. Biotechnol. Biochem.* 57, 2127–2132. doi: 10.1271/bbb.57.2127
- Lee, M. H., Yoo, S.-H., Ha, S.-D., and Choi, C. (2012). Inactivation of feline calicivirus and murine norovirus during Dongchimi fermentation. *Food Microbiol.* 31, 210–214. doi: 10.1016/j.fm.2012.04.002
- Li, D., Breiman, A., Le Pendu, J., and Uyttendaele, M. (2015). Binding to histo-blood group antigen-expressing bacteria protects human norovirus from acute heat stress. *Front. Microbiol.* 6:659. doi: 10.3389/fmicb.2015.00659
- Lipton, H. L. (1980). Persistent theiler’s murine encephalomyelitis virus infection in mice depends on plaque size. *J. Gen. Virol.* 46, 169–177. doi: 10.1099/0022-1317-46-1-169
- Ljungh, A., and Wadström, T. (2006). Lactic acid bacteria as probiotics. *Curr. Issues Intest. Microbiol.* 7, 73–90.
- Mao, X., Gu, C., Hu, H., Tang, J., Chen, D., Yu, B., et al. (2016). Dietary *Lactobacillus rhamnosus* GG supplementation improves the mucosal barrier function in the intestine of weaned piglets challenged by porcine rotavirus. *PLoS ONE* 11:e0146312. doi: 10.1371/journal.pone.0146312
- Maragkoudakis, P. A., Chingwaru, W., Gradisnik, L., Tsakalidou, E., and Cencic, A. (2010). Lactic acid bacteria efficiently protect human and animal intestinal epithelial and immune cells from enteric virus infection. *Int. J. Food Microbiol.* 141, S91–S97. doi: 10.1016/j.ijfoodmicro.2009.12.024
- Muñoz, J. A. M., Chenoll, E., Casinos, B., Bataller, E., Ramón, D., Genovés, S., et al. (2011). Novel probiotic *Bifidobacterium longum* subsp. infantis CECT 7210 strain active against rotavirus infections. *Appl. Environ. Microbiol.* 77, 8775–8783. doi: 10.1128/AEM.05548-11
- Puniya, A. K. (2015). *Fermented Milk and Dairy Products*. Boca Raton, FL: CRC Press, 105.
- Rubio-del-Campo, A., Coll-Marqués, J. M., Yebra, M. J., Buesa, J., Pérez-Martínez, G., Monedero, V., et al. (2014). Noroviral p-particles as an in vitro model to assess the interactions of noroviruses with probiotics. *PLoS ONE* 9:e89586. doi: 10.1371/journal.pone.0089586
- Saavedra, J. M., Bauman, N., Perman, J., Yolken, R., and Oung, I. (1994). Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. *Lancet* 344, 1046–1049. doi: 10.1016/S0140-6736(94)91708-6
- Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., et al. (2013). An update on the use and investigation of probiotics in health and disease. *Gut* 62, 787–796. doi: 10.1136/gutjnl-2012-302504
- Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S., and Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. *Lancet Infect. Dis.* 6, 374–382. doi: 10.1016/S1473-3099(06)70495-9
- Seo, D. J., Lee, M. H., Seo, J., Ha, S.-D., and Choi, C. (2014). Inactivation of murine norovirus and feline calicivirus during oyster fermentation. *Food Microbiol.* 44, 81–86. doi: 10.1016/j.fm.2014.05.016
- Shearer, A. E., Hoover, D. G., and Kniel, K. E. (2014). Effect of bacterial cell-free supernatants on infectivity of norovirus surrogates. *J. Food Protect.* 77, 145–149. doi: 10.4315/0362-028X.JFP-13-204
- Takemoto, K. K. (1966). Plaque mutants of animal viruses. *Prog. Med. Virol.* 8, 314–348.
- Tamura, M., Natori, K., Kobayashi, M., Miyamura, T., and Takeda, N. (2004). Genogroup II noroviruses efficiently bind to heparin sulfate proteoglycan associated with the cellular membrane. *J. Virol.* 78, 3817–3826. doi: 10.1128/JVI.78.8.3817-3826.2004
- Tan, M., and Jiang, X. (2011). Norovirus-host interaction: multi-selections by human histo-blood group antigens. *Trends Microbiol.* 19, 382–388. doi: 10.1016/j.tim.2011.05.007
- Van Beek, J., Ambert-Balay, K., Botteldoorn, N., Eden, J., Fonager, J., Hewitt, J., et al. (2013). Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II. 4, late 2012. *Euro Surveill.* 18, 8–9.
- Van Niel, C. W., Feudtner, C., Garrison, M. M., and Christakis, D. A. (2002). *Lactobacillus* therapy for acute infectious diarrhea in children: a meta-analysis. *Pediatrics* 109:e52. doi: 10.1542/peds.109.4.678
- Wobus, C. E., Karst, S. M., Thackray, L. B., Chang, K., Sosnovtsev, S. V., Belliot, G., et al. (2004). Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. *PLoS Biol.* 2:e432. doi: 10.1371/journal.pbio.0020432
- Zhong, S.-S., Zhang, Z.-S., Wang, J.-D., Lai, Z.-S., Wang, Q.-Y., Pan, L.-J., et al. (2004). Competitive inhibition of adherence of enterotoxigenic *Escherichia coli*, enteropathogenic *Escherichia coli* and *Clostridium difficile* to intestinal epithelial cell line Lovo by purified adhesin of *Bifidobacterium adolescentis* 1027. *World J. Gastroenterol.* 10, 1630–1633. doi: 10.3748/wjg.v10.i11.1630

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Li, Breiman, le Pendu and Uyttendaele. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.